Review: taking Isoniazid and Rifampin together


Summary

Drug interactions are reported among people who take Isoniazid and Rifampin together. This review analyzes the effectiveness and drug interactions between Isoniazid and Rifampin. It is created by eHealthMe based on reports of 1,192 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Isoniazid and Rifampin >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Isoniazid

Isoniazid has active ingredients of isoniazid. It is often used in tuberculosis. (latest outcomes from Isoniazid 8,394 users)

Rifampin

Rifampin has active ingredients of rifampin. It is often used in tuberculosis. (latest outcomes from Rifampin 2,530 users)

On Aug, 25, 2016

1,192 people who take Isoniazid, Rifampin are studied.


Number of reports submitted per year:

Isoniazid and Rifampin drug interactions.

Drug effectiveness over time:

Isoniazid:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 44.0% - (4 of 9 people)
  • 6 - 12 months: 100.0% - (3 of 3 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Rifampin:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 44.0% - (4 of 9 people)
  • 6 - 12 months: 100.0% - (3 of 3 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Isoniazid:
  • female: 77.0% - (7 of 9 people)
  • male: 25.0% - (1 of 4 people)
Rifampin:
  • female: 77.0% - (7 of 9 people)
  • male: 25.0% - (1 of 4 people)

Drug effectiveness by age:

Isoniazid:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 75.0% - (3 of 4 people)
  • 30-39: 50.0% - (2 of 4 people)
  • 40-49: 100.0% - (2 of 2 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 50.0% - (1 of 2 people)
Rifampin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 75.0% - (3 of 4 people)
  • 30-39: 50.0% - (2 of 4 people)
  • 40-49: 100.0% - (2 of 2 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 50.0% - (1 of 2 people)

Most common drug interactions over time *:

< 1 month:
  • renal failure acute
  • pyrexia
  • cytolytic hepatitis
  • hepatitis
  • headache
  • cholestasis
  • hepatic encephalopathy
  • hepatitis fulminant
  • liver disorder
  • multi-organ failure
1 - 6 months:
  • pyrexia
  • cytolytic hepatitis
  • hepatitis fulminant
  • neutropenia
  • drug eruption
  • leukopenia
  • renal failure acute
  • eosinophilia
  • drug rash with eosinophilia and systemic symptoms
  • dyspnoea
6 - 12 months:
  • convulsion
  • ocular icterus
  • deafness
  • hypoacusis
  • optic neuropathy
  • blood alkaline phosphatase increased
  • cerebral toxoplasmosis
  • cholangitis
  • cholestasis
  • chorioretinitis
1 - 2 years:
  • acne
  • blood cholesterol
  • thrombocytopenia
  • disturbance in attention
  • hypothermia
  • lung disorder
  • mental disorder
  • pulmonary thrombosis
  • renal failure chronic
  • respiratory distress
2 - 5 years:
  • disturbance in attention
  • paraesthesia
  • mental disorder
  • somnolence
  • cerebral ischaemia
  • diplopia
  • drug eruption
  • dysarthria
  • fatigue
  • meningism
5 - 10 years:
  • stevens johnson syndrome
not specified:
  • pyrexia
  • renal failure acute
  • thrombocytopenia
  • aspartate aminotransferase increased
  • alanine aminotransferase increased
  • nausea
  • tuberculosis
  • liver function tests nos abnormal
  • weight decreased
  • immune reconstitution syndrome

Most common drug interactions by gender *:

female:
  • pyrexia
  • hepatitis fulminant
  • alanine aminotransferase increased
  • hepatic encephalopathy
  • nausea
  • aspartate aminotransferase increased
  • cytolytic hepatitis
  • hepatic failure
  • tuberculosis
  • cholestasis
male:
  • pyrexia
  • renal failure acute
  • dyspnoea
  • thrombocytopenia
  • neutropenia
  • drug eruption
  • liver disorder
  • aspartate aminotransferase increased
  • convulsion
  • cough

Most common drug interactions by age *:

0-1:
  • immune reconstitution syndrome
  • acute hepatic failure
  • bovine tuberculosis
  • brain oedema
  • coagulopathy
  • hepatic encephalopathy
  • hepatic failure
  • lymphadenitis
  • pyrexia
  • abdominal distension
2-9:
  • pyrexia
  • paradoxical drug reaction
  • acinetobacter infection
  • acute hepatic failure
  • arterial occlusive disease
  • arteritis
  • blood alkaline phosphatase increased
  • cardiac arrest
  • carotid artery stenosis
  • central nervous system infection
10-19:
  • pyrexia
  • acute hepatic failure
  • renal failure acute
  • drug level increased
  • eosinophilia
  • lymphadenopathy
  • paradoxical drug reaction
  • thrombocytopenia
  • acute respiratory distress syndrome
  • cough
20-29:
  • pyrexia
  • aspartate aminotransferase increased
  • nausea
  • hepatic failure
  • alanine aminotransferase increased
  • immune reconstitution syndrome
  • blood creatine phosphokinase increased
  • hepatic necrosis
  • weight decreased
  • diarrhoea
30-39:
  • pyrexia
  • renal failure acute
  • hepatitis fulminant
  • immune reconstitution syndrome
  • deep vein thrombosis
  • general physical health deterioration
  • lymphadenopathy
  • pulmonary embolism
  • cough
  • cytolytic hepatitis
40-49:
  • pyrexia
  • vomiting
  • hepatitis fulminant
  • diarrhoea
  • anaemia
  • aspartate aminotransferase increased
  • dyspnoea
  • hepatic encephalopathy
  • hepatitis
  • renal failure acute
50-59:
  • renal failure acute
  • drug eruption
  • pyrexia
  • leukopenia
  • neutropenia
  • stevens-johnson syndrome
  • convulsion
  • dyspnoea
  • blood bilirubin increased
  • general physical health deterioration
60+:
  • pyrexia
  • thrombocytopenia
  • liver disorder
  • renal failure acute
  • liver function tests nos abnormal
  • cholestasis
  • hepatic failure
  • pleural effusion
  • hepatic function abnormal
  • hepatocellular damage

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Isoniazid and Rifampin?

Can you answer these questions?

More questions for: Isoniazid, Rifampin

You may be interested in these reviews

More reviews for: Isoniazid, Rifampin

On eHealthMe, Isoniazid (isoniazid) is often used to treat tuberculosis. Rifampin (rifampin) is often used to treat tuberculosis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.